These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Leukemia AND CREBBP, CBP, 1387, ENSG00000005339, RSTS, RTS
506 results:

  • 1. Clinicopathological characteristics and genomic profiling in patients with transformed lymphoma: a monocentric retrospective study.
    Zhao X; Bian H; Hao F; Shao S; Wu C; Zhang Q; Wu M; Li Z; Gao C
    Ann Med; 2024 Dec; 56(1):2419556. PubMed ID: 39460552
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. PBA2, a novel inhibitor of the β-catenin/cbp pathway, eradicates chronic myeloid leukemia including BCR-ABL T315I mutation.
    Yang K; Fu K; Zhang H; Wang X; To KKW; Yang C; Wang F; Chen ZS; Fu L
    Mol Cancer; 2024 Sep; 23(1):209. PubMed ID: 39342174
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Genomic Determinants of Outcome in Acute Lymphoblastic leukemia.
    Chang TC; Chen W; Qu C; Cheng Z; Hedges D; Elsayed A; Pounds SB; Shago M; Rabin KR; Raetz EA; Devidas M; Cheng C; Angiolillo A; Baviskar P; Borowitz M; Burke MJ; Carroll A; Carroll WL; Chen IM; Harvey R; Heerema N; Iacobucci I; Wang JR; Jeha S; Larsen E; Mattano L; Maloney K; Pui CH; Ramirez NC; Salzer W; Willman C; Winick N; Wood B; Hunger SP; Wu G; Mullighan CG; Loh ML
    J Clin Oncol; 2024 Oct; 42(29):3491-3503. PubMed ID: 39121442
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. GNAS knockout potentiates HDAC3 inhibition through viral mimicry-related interferon responses in lymphoma.
    He MY; Tong KI; Liu T; Whittaker Hawkins R; Shelton V; Zeng Y; Bakhtiari M; Xiao Y; Zheng G; Sakhdari A; Yang L; Xu W; Brooks DG; Laister RC; He HH; Kridel R
    Leukemia; 2024 Oct; 38(10):2210-2224. PubMed ID: 39117798
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Identification of genetic subtypes in follicular lymphoma.
    Shelton V; Detroja R; Liu T; Isaev K; Silva A; Passerini V; Bakhtiari M; Calvente L; Hong M; He MY; Modi S; Hershenfeld SA; Ludvigsen M; Madsen C; Hamilton-Dutoit S; d'Amore FA; Brodtkorb M; Johnson NA; Baetz T; LeBrun D; Tobin JWD; Gandhi MK; Mungall AJ; Xu W; Ben-Neriah S; Steidl C; Delabie J; Tremblay-LeMay R; Jegede O; Weigert O; Kahl B; Evens AM; Kridel R
    Blood Cancer J; 2024 Aug; 14(1):128. PubMed ID: 39112453
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Silencing GNAS enhances HDAC3i efficacy in crebbp wild type B cell lymphoma.
    Mondello P
    Leukemia; 2024 Oct; 38(10):2087-2089. PubMed ID: 39030358
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. MYB as a Critical Transcription Factor and Potential Therapeutic Target in AML.
    Clarke ML; Gabrielsen OS; Frampton J
    Adv Exp Med Biol; 2024; 1459():341-358. PubMed ID: 39017851
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Evaluating the accuracy of Raman spectroscopy in differentiating leukemia patients from healthy individuals: A systematic review and meta-analysis.
    Li S; Gao S; Su L; Zhang M
    Photodiagnosis Photodyn Ther; 2024 Aug; 48():104260. PubMed ID: 38950876
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. A MOZ-TIF2 leukemia mouse model displays KAT6-dependent H3K23 propionylation and overexpression of a set of active developmental genes.
    Smolko AE; Sullivan DW; Olsen SN; Kang H; Whedon SD; Baell JB; Cole PA; Armstrong SA; Kuroda MI
    Proc Natl Acad Sci U S A; 2024 Jun; 121(26):e2405905121. PubMed ID: 38889153
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Discovery of a Promising cbp/p300 Degrader XYD129 for the Treatment of Acute Myeloid leukemia.
    Wu T; Hu J; Zhao X; Zhang C; Dong R; Hu Q; Xu H; Shen H; Zhang X; Zhang Y; Lin B; Wu X; Xiang Q; Xu Y
    J Med Chem; 2024 Jun; 67(11):9194-9213. PubMed ID: 38829718
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. The DNA damage-independent ATM signalling maintains cbp/DOT1L axis in MLL rearranged acute myeloid leukaemia.
    Wang G; Zhang W; Ren J; Zeng Y; Dang X; Tian X; Yu W; Li Z; Ma Y; Yang P; Lu J; Zheng J; Lu B; Xu J; Liang A
    Oncogene; 2024 Jun; 43(25):1900-1916. PubMed ID: 38671157
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Discovery of Highly Potent and Efficient cbp/p300 Degraders with Strong
    Hu J; Xu H; Wu T; Zhang C; Shen H; Dong R; Hu Q; Xiang Q; Chai S; Luo G; Chen X; Huang Y; Zhao X; Peng C; Wu X; Lin B; Zhang Y; Xu Y
    J Med Chem; 2024 May; 67(9):6952-6986. PubMed ID: 38649304
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. The RAS-signaling-pathway-mutation-related prognosis in B-cell acute lymphoblastic leukemia: A report from South China children's leukemia group.
    Li X; Lin S; Liao N; Mai H; Long X; Liu L; Wu B; Chen Q; Kong Q; Kong X; Liu L; Qin J; Fang J; Zhou D
    Hematol Oncol; 2024 May; 42(3):e3265. PubMed ID: 38564328
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Genomic imbalance analysis provides new insight into prognostic factors in adult and pediatric T-ALL.
    Balducci E; Simonin M; Duployez N; Steimlé T; Dourthe ME; Villarese P; Ducassou S; Arnoux I; Cayuela JM; Balsat M; Courtois L; Andrieu G; Touzart A; Huguet F; Petit A; Ifrah N; Dombret H; Baruchel A; Macintyre E; Preudhomme C; Boissel N; Asnafi V
    Blood; 2024 Aug; 144(9):988-1000. PubMed ID: 38518104
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Inhibition of CREB Binding and Function with a Dual-Targeting Ligand.
    Liu Y; Joy ST; Henley MJ; Croskey A; Yates JA; Merajver SD; Mapp AK
    Biochemistry; 2024 Jan; 63(1):1-8. PubMed ID: 38086054
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Therapeutic targeting of EP300/cbp by bromodomain inhibition in hematologic malignancies.
    Nicosia L; Spencer GJ; Brooks N; Amaral FMR; Basma NJ; Chadwick JA; Revell B; Wingelhofer B; Maiques-Diaz A; Sinclair O; Camera F; Ciceri F; Wiseman DH; Pegg N; West W; Knurowski T; Frese K; Clegg K; Campbell VL; Cavet J; Copland M; Searle E; Somervaille TCP
    Cancer Cell; 2023 Dec; 41(12):2136-2153.e13. PubMed ID: 37995682
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Discovery of a potent and selective cbp bromodomain inhibitor (Y08262) for treating acute myeloid leukemia.
    Xiang Q; Wu T; Zhang C; Wang C; Xu H; Hu Q; Hu J; Luo G; Zhuang X; Wu X; Zhang Y; Xu Y
    Bioorg Chem; 2024 Jan; 142():106950. PubMed ID: 37924753
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. DUX4-r exerts a neomorphic activity that depends on GTF2I in acute lymphoblastic leukemia.
    Campolungo D; Salomé M; Biferali B; Tascini AS; Gabellini D
    Sci Adv; 2023 Sep; 9(37):eadi3771. PubMed ID: 37713484
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. A Deeply Quiescent Subset of CML LSC depend on FAO yet Avoid Deleterious ROS by Suppressing Mitochondrial Complex I.
    Chimge NO; Chen MH; Nguyen C; Zhao Y; Wu X; Gonzalez PG; Ogana H; Hurwitz S; Teo JL; Chen X; Du J; Jin V; Kim YM; Ono M; Argüello RJ; Kahn M
    Curr Mol Pharmacol; 2024; 17(1):e060923220758. PubMed ID: 37691195
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. [A comparative study of the effects of citrate and heparin anticoagulation on coagulation function and efficacy in children with septic shock undergoing continuous blood purification].
    Zhong X; Luo S; Ren R; Lai J; Deng G; Zhu H
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2023 Aug; 35(8):856-859. PubMed ID: 37593866
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 26.